PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

The FDA has agreed to review the New Drug Application (NDA) for D-PLEX100 with priority status. The Prescription Drug User Fee Act (PDUFA) goal date is set for November 28, 2026, about three months earlier than originally expected.